Inappropriate Medications Associated With Anticholinesterase and/or Memantine Treatment in the Elderly

Inappropriate Medications and Alzheimer Disease: Prevalence and Associated Factors in Elderly Patients Treated With Anticholinesterase and/or Memantine. MIDA Study.

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00954616

Acronym

MIDA

Enrollment

636

Registered

2009-08-07

Start date

2009-01-31

Completion date

2012-01-31

Last updated

2014-03-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alzheimer's Disease

Keywords

Inappropriate Medications Associated, Alzheimer's disease

Brief summary

In each of the 7 French areas that should be involved, patients aged 75 years and over from three different sectors will be included: the geriatric consultation unit (60%) and two kinds of nursing homes, private (20%) and state (10%). Outpatients will be included in chronological order; patients in nursing homes will be included at random. The patients and their families will be asked about the treatments received on the day of inclusion. The inclusion period will extend over a year. The investigating practitioners will be asked to fill in a questionnaire reporting the main clinical data, adverse effects occurrence, and information on the treatment given.

Interventions

None listed

Study design

Observational model

CASE_ONLY

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

75 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patients aged 75 years and over identified as having Alzheimer disease and who have been treated for more than 3 months with anticholinesterase and/or memantine

Exclusion criteria

* Patients with decompensated chronic condition or acute phase disease

Design outcomes

Primary

Measure	Time frame
To evaluate the prevalence of PIM use in patients aged 75 years and over treated with anticholinesterase and/or memantine	2 years

Secondary

Measure	Time frame
To identify factors associated with PIM use. To study the relationship between PIM exposure and adverse effects occurrence.	2 years

Countries

France

Outcome results